List of SBIR/STTR awards granted to Vivreon Biosciences Llc
Vivreon Biosciences LlcName | Description | SBIR/STTR Award Recipient | Government Agency | Government Branch | Award Type | Contract Number (US Government) | Award Phase | Award Amount (USD) | Date Awarded | Official Website | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
A SBIR Phase I contract was awarded to Vivreon Biosciences Llc in September, 2021 for $252,039.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43AR079968-01A1 | Phase I | 252,039 | September 22, 2021 | |||||||
A SBIR Phase II contract was awarded to Vivreon Biosciences Llc in September, 2022 for $1,276,596.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 2R44AG061995-02A1 | Phase II | 1,276,596 | September 15, 2022 | |||||||
A SBIR Phase I contract was awarded to Vivreon Biosciences Llc in May, 2022 for $299,989.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43AI165096-01A1 | Phase I | 299,989 | May 1, 2022 | |||||||
A SBIR Phase II contract was awarded to Vivreon Biosciences Llc in September, 2019 for $1,004,278.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 2R44CA224454-02 | Phase II | 1,004,278 | September 1, 2019 | |||||||
A SBIR Phase I contract was awarded to Vivreon Biosciences Llc in August, 2019 for $270,902.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43AG061995-01A1 | Phase I | 270,902 | August 1, 2019 | |||||||
A SBIR Phase II contract was awarded to Vivreon Biosciences Llc in June, 2019 for $1,250,000.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 2R44AG055205-04 | Phase II | 1,250,000 | June 15, 2019 | |||||||
A SBIR Phase I contract was awarded to Vivreon Biosciences Llc in March, 2018 for $225,000.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43CA224454-01A1 | Phase I | 225,000 | March 2, 2018 | |||||||
A SBIR Phase I contract was awarded to Vivreon Biosciences Llc in September, 2022 for $245,256.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43AR081158-01A1 | Phase I | 245,256 | September 15, 2022 | |||||||
A SBIR Phase I contract was awarded to Vivreon Biosciences Llc in September, 2020 for $349,967.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43DA053010-01 | Phase I | 349,967 | September 1, 2020 | |||||||
A SBIR Phase II contract was awarded to Vivreon Biosciences Llc in June, 2022 for $1,371,030.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R44CA268541-01A1 | Phase II | 1,371,030 | June 1, 2022 | |||||||
A SBIR Phase I contract was awarded to Vivreon Biosciences Llc in September, 2016 for $222,453.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R44AG055205-01 | Phase I | 222,453 | September 30, 2016 | |||||||
A SBIR Phase I contract was awarded to Vivreon Biosciences Llc in July, 2017 for $219,975.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43AI134205-01 | Phase I | 219,975 | July 1, 2017 | |||||||
A SBIR Phase II contract was awarded to Vivreon Biosciences Llc in August, 2017 for $1,492,301.0 USD from the U.S. Department of Health & Human Services. | SBIR | 4R44AG055205-02 | Phase II | 1,492,301 | August 1, 2017 | |||||||
A SBIR Phase I contract was awarded to Vivreon Biosciences Llc in July, 2023 for $319,991.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R44DA058467-01 | Phase I | 319,991 | July 15, 2023 | |||||||
A SBIR Phase I contract was awarded to Vivreon Biosciences Llc in April, 2023 for $352,030.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43HL167426-01 | Phase I | 352,030 | April 15, 2023 |
